Basic Information
| LncRNA/CircRNA Name | LINC00673 |
| Synonyms | LINC00673, HI-LNC75, HILNC75, LUCAIR1, SLNCR, SLNCR1 |
| Region | GRCh38_17:72403322-72592804 |
| Ensemble | NA |
| Refseq | NR_036488 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic cancer |
| ICD-0-3 | C25 |
| Methods | qPCR, Flow cytometry assay etc. |
| Sample | pancreatic cancer tissues, cell lines (BXPC-3 and CFPAC-1) |
| Expression Pattern | up-regulated |
| Function Description | Flow cytometry analysis indicated that LINC00673 overexpression resulted in a substantial accumulation of PDAC cells in G0/G1 phase, accompanied by a substantial decrease in the number of cells in S phase. LINC00673 is able to reinforce the interaction of PTPN11 with PRPF19, an E3 ubiquitin ligase, and promote PTPN11 degradation through ubiquitination, which causes diminished SRC-ERK oncogenic signaling and enhanced activation of the STAT1-dependent antitumor response. A G>A change at rs11655237 in exon 4 of LINC00673 creates a target site for miR-1231 binding, which diminishes the effect of LINC00673 in an allele-specific manner and thus confers susceptibility to tumorigenesis. |
| Pubmed ID | 27213290 |
| Year | 2016 |
| Title | Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. |
External Links
| Links for LINC00673 | GenBank HGNC NONCODE |
| Links for pancreatic cancer | OMIM COSMIC |